`Petitioner’s Motion to Seal
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________________
`
`Altaire Pharmaceuticals, Inc.
`
`Petitioner
`
`v.
`
`Paragon BioTeck, Inc.
`
`Patent Owner
`
`
`
`U.S. Patent No. 8,859,623
`Issue Date: October 14, 2014
`Entitled: METHODS AND COMPOSITIONS OF STABLE PHENYLEPHRINE
`FORMULATIONS
`
`____________________
`
`Post-Grant Review No.: PGR2015-00011
`____________________
`
`PETITIONER’S MOTION TO SEAL
`
`
`
`
`
`Document Number: 3327905
`
`
`
`U.S. Patent No. 8,859,623
`Petitioner’s Motion to Seal
`
`I.
`
`
`STATEMENT OF RELIEF REQUESTED
`
`Pursuant to 37 C.F.R. § 42.14 and the previously submitted Protective
`
`Order (Exh. 2012), Altaire Pharmaceuticals, Inc. (“Petitioner”) respectfully moves
`
`to seal its Reply to Patent Owner’s Preliminary Statement (“Petitioner’s Reply”)
`
`and its supporting declaration Exhibit 1022. As detailed below, Petitioner’s Reply
`
`and the supporting declaration contain information that Paragon BioTeck, Inc.
`
`(“Paragon” or “Patent Owner”) considers highly confidential and extremely
`
`sensitive and does not wish made publicly available.
`
`II.
`
`
`
`PARAGON ASSERTS GOOD CAUSE EXISTS FOR SEALING
`INFORMATION
`
`Petitioner seeks to file its Reply and supporting declaration under seal
`
`solely out of caution. As asserted in its Motion to Seal filed August 24, 2015,
`
`Paragon asserts this information is not publicly available, and that disclosure of
`
`this information would significantly harm Paragon. See Patent Owner’s Motion to
`
`Seal and Motion for entry of Protective Order Pursuant to 37. C.F.R. § 42.14 and §
`
`42.54, PGR2015-00011, Paper 6, 2 (P.T.A.B. 2015).
`
`
`
`As such, Petitioner has redacted only the specific information relating to
`
`the Agreement that Paragon has previously redacted from Exhibit 2004. See Table
`
`1 infra.
`
`1
`
`
`
`
`
`U.S. Patent No. 8,859,623
`
`Petitioner’s Motion to Seal
`
`Pg. 5, l. 8
`
`Petitioner;s'.'Reply
`
`Paper No. 9
`
`Exhibit 1022
`
`Declaration of Assad
`
`Pg. 1, 11. 14-15
`
`Pg. 9, 11. 12-16
`
`Sawaya in Support of
`
`Petitioner’s Reply
`
`Pg. 2, 1. 15
`
`Pg. 3, 11. 7-10
`
`Dated: September 28, 2015
`
`Respectfully submitted, W
`
`
`1
`Dipu A. Do%1:i~.~-»»»»»»»»»P
`Registration No.: 60,073
`Edward A. Meilman
`
`Registration No.: 24,735
`DICKSTEIN SHAPIRO LLP
`
`1825 Eye Street, NW
`Washington, DC 20006-5403
`(202) 420-2200
`Attorneys for Petitioner
`
`
`
`
`
`
`
`
`
`Reply to Patent Owner’s Preliminary Statement
`Docket No.: A3996.0018
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that a true copy of the foregoing PETITIONER’S
`
`MOTION TO SEAL has been served in its entirety this 28th day of September,
`
`2015, by e-mail on:
`
`Michael T. Rosato
`Steven W. Parmelee
`WILSON, SONSINI, GOODRICH & ROSATI
`701 Fifth Avenue
`Suite 5100
`Seattle, WA 98104-7036
`mrosato@wsgr.com
`sparmelee@wsgr.com
`
`
`
`/s/ Dipu A. Doshi
`Dipu A. Doshi
`Registration No. 60,073
`Attorney for Altaire Pharmaceuticals, Inc.
`
`
`DICKSTEIN SHAPIRO LLP
`1825 Eye Street, NW
`Washington, DC 20006
`Tel.: (202) 420-2200
`Facsimile: (202) 420-2201